PathGroup and uMETHOD Health Partner to Personalize Care for Mild Cognitive Impairment (MCI) and Early-stage Alzheimer’s Disease Patients
By Eric Quimby
NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ — uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD’s AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient’s risk of developing Alzheimer’s and disease progression in its early stages. Read the full release.
A leading user of PathGroup services, Dr. Rodney Roberts from Decatur, TN describes his experience with RestoreU. "The complexity of Alzheimer's disease and other forms of cognitive impairment make it difficult to manage in a primary care setting. I'm thankful PathGroup brought RestoreU to our attention as this is the best solution I've found to address memory loss for my patients. Thanks to the partnership with uMETHOD, we can take a data-driven approach to patient care that this devastating disease requires."
